4basebio CEO on disrupting the $3bn DNA market with synthetic alternative

4basebio PLC (AIM:4BB, FRA:8L7, ETR:88Q) CEO Amy Walker joined Proactive's Stephen Gunnion to discuss the company's synthetic DNA platform, growing commercial momentum and key milestones for investors.
Walker explained how 4basebio's enzyme-based technology provides a cleaner, faster and more cost-effective alternative to conventional plasmid DNA manufacturing, supporting applications in cell and gene therapy, vaccines and gene editing. She also highlighted the launch of the company's single-stranded DNA product, which offers lower toxicity and the ability to produce longer DNA molecules for advanced gene editing.
The interview also covers a recent Phase 2 clinical supply agreement, the appointment of mRNA expert Jeff Coller to the Strategic Advisory Board, expansion of the company's Cambridge manufacturing facility and the commercial milestones investors should watch for over the coming months.
For more interviews and market insights, visit Proactive's YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications so you never miss future content.
#4basebio #SyntheticDNA #DNAManufacturing #GeneEditing #CRISPR #CellTherapy #GeneTherapy #Biotech #Biotechnology #LifeSciences #mRNA #Vaccines #PersonalizedMedicine #CancerVaccines #HealthcareInnovation #ClinicalTrials #CambridgeBiotech #Investing #SmallCapStocks #ProactiveInvestors